Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Go back to Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 14.67 -0.19 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.86 | 52 Week High | $5.58 | |||
| Open | $14.59 | 52 Week Low | $3.60 | |||
| Day High | $14.72 | P/E | N/A | |||
| Day Low | $14.54 | EPS | $0.00 | |||
| Volume | 5,201,520 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 42.82 -0.33 (0.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.15 | 52 Week High | $44.76 | |||
| Open | $43.08 | 52 Week Low | $36.81 | |||
| Day High | $43.46 | P/E | N/A | |||
| Day Low | $42.82 | EPS | $0.00 | |||
| Volume | 1,615,692 | |||||
